Wheels of horizon

  The global floriculture market comprises cultivation and trade of cut flowers and ornamental or potted plants. It involves propagating, growing, harvesting, and bringing flowers and ornamental plants to market. The industry has witnessed considerable growth over the past few years owing to increased consumer spending on gifts, occasions, parties, and other events. Global floriculture market was valued at US$ 54.2 Bn in 2022 in terms of revenue, exhibiting a CAGR of 7.66 % during the forecast period (2023 to 2030). Floriculture Market Demand has become a profitable business worldwide as flowers carry cultural, religious and emotional value. The availability of varied and exotic flowers throughout the year due to modern greenhouse cultivation is driving the demand. Key Takeaways Key players - Key players operating in the floriculture are Floranext, Karuturi Global Ltd., Fluonia, Flower Soul, Verbeek Export B.V, and Selecta one. Key opportunities - Rising demand for exotic fl...

  What is a Vendor Neutral Archive (VNA) Industry)? A vendor neutral archive (VNA) is a medical imaging software system and data storage device that separate DICOM and non-DICOM unstructured content from proprietary features of the modality vendor. A VNA acts as a universal repository for all medical images and related digital files, regardless of where and how the content was captured or stored. This includes images from departments like radiology, cardiology, dermatology etc. Need and Benefits of a Vendor Neutral Archive (VNA) Industry The adoption of a Vendor Neutral Archive (VNA) provides several important benefits to healthcare organizations. Some of the key needs and benefits of deploying a VNA include: Interoperability and Standardization One of the main purposes of a VNA is to provide interoperability across different clinical systems. Images and related data stored in a VNA follow open DICOM standards to ensure accessibility from any network-connected image view...

 Ventricular assist devices (VADs) are mechanical circulatory devices that are implanted in patients with weakened hearts that cannot pump enough blood to the rest of the body. They assist the heart in pumping blood and act as a bridge to transplant for patients awaiting a donor heart or a destination therapy for patients ineligible for a heart transplant. The growing cases of heart failure coupled with technological advancements in cardiac assist devices is driving the adoption of ventricular assist devices. According to the American Heart Association, around 6.2 million adults in the U.S. suffer from heart failure and this number is expected to increase 46% by 2030. The Global Ventricular Assist Devices Market is estimated to be valued at US$ 3.6 billion in 2024 and is expected to exhibit a CAGR of 5.3% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the Ventricular Assist Devices market are Medtronic, Abbott Laboratories, Abiomed, Berlin Heart,...

 The ship-to-shore crane market has been witnessing significant growth driven by growing containerized trade worldwide and expansion of port infrastructure to enhance cargo handling capacity. Ship-to-shore cranes, also known as port cranes, are large dockside gantry cranes used for loading and unloading container ships at container terminals. They play a vital role in seamless transfer of cargo boxes between ships and shore in an efficient manner. Rise in container trade has propelled investments into modernizing equipment and technologies used at ports. Ship-to-shore cranes are integral to port operations as they facilitate rapid movement of containers while minimizing turnaround time of vessels. The global ship-to-shore crane market is estimated to be valued at US$ 2.8 Billion in 2024 and is expected to exhibit a CAGR of 4.3% over the forecast period 2024-2032. Growing international seaborne trade, especially container trade, has necessitated expansion of global port capacity...

  Development of Telehealth Services Industry Around the Globe Telehealth services have seen rapid growth in many countries over the past decade as technology has advanced. A few countries have particularly led the way in adopting and expanding telehealth programs. In the United States, the Veterans Health Administration was an early adopter of Telehealth Services back in the 1990s and has continued expanding its virtual care offerings. Private insurers have also increasingly covered telehealth visits in recent years. The pandemic led to relaxation of rules preventing reimbursement for virtual visits, fueling further growth. It's estimated over a third of all healthcare visits in the U.S. will involve telehealth by 2025. Countries in Europe have also invested heavily in national telehealth platforms. For example, Sweden launched its National Telemedicine Strategy in 2010 to connect rural areas to specialists in cities. Over 90% of Swedish municipalities now offer some form of t...

 The alopecia treatment market holds immense growth potential owing to the rising cases of alopecia disorders worldwide. The market consists of various treatment options for alopecia such as topical and oral therapeutic drugs, hair transplant services, low-level laser therapy, and vitamin supplements that aid in hair regrowth. These treatment options facilitate hair regrowth by controlling excess hair fall and stimulating existing hair follicles. Global alopecia treatment market is estimated to be valued at US$ 9.65 Bn in 2023, and is expected to exhibit a CAGR of 5.6% during the forecast period (2023-2030). Key Takeaways Key players operating in the alopecia treatment market are Johnson & Johnson Services, Inc., Merck & Co. Inc., Alpecin, Cipla Inc., Viviscal, and Kirkland Signature. These players are adopting several organic and inorganic growth strategies such as new product launches, acquisitions, and collaborations to strengthen their market presence. The rising ...

The preclinical assets market involves compound optimization, lead identification, target validation, and assays related to drug discovery and development prior to the initiation of human clinical trials. Preclinical assets including chemical compounds, biologics and drug targets play a pivotal role in early drug development and screening. Factors such as rising R&D expenditures by pharmaceutical & biotechnology companies and increasing government funding for preclinical research have fueled market growth. Preclinical Assets Market is estimated to be valued at US$ 1.2 Billion in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031. Key Takeaways Key players operating in the preclinical assets market are Merck & Co, Pfizer Inc, Eli Lilly and Company, Thermo Fisher Scientific, GE Healthcare. The rising prevalence of chronic diseases and increasing Preclinical Assets Market Demand for targeted therapies are projected to create new opportuniti...